Literature DB >> 19016756

Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer.

Kokichi Sugano1, Seigo Nakamura, Jiro Ando, Shin Takayama, Hiroyuki Kamata, Isao Sekiguchi, Megumi Ubukata, Tetsuro Kodama, Masami Arai, Fujio Kasumi, Yasuo Hirai, Tadashi Ikeda, Hiromitsu Jinno, Masaki Kitajima, Daisuke Aoki, Akira Hirasawa, Yuko Takeda, Kumiko Yazaki, Takashi Fukutomi, Takayuki Kinoshita, Ryuichiro Tsunematsu, Teruhiko Yoshida, Masako Izumi, Shino Umezawa, Hiroshi Yagata, Hiroko Komatsu, Naoko Arimori, Noriko Matoba, Nobuhisa Gondo, Shiro Yokoyama, Yoshio Miki.   

Abstract

The prevalence of BRCA1/2 germline mutations in Japanese patients suspected to have hereditary breast/ovarian cancer was examined by a multi-institutional study, aiming at the clinical application of total sequencing analysis and validation of assay sensitivity in Japanese people using a cross-sectional approach based on genetic factors estimated from personal and family histories. One hundred and thirty-five subjects were referred to the genetic counseling clinics and enrolled in the study. Full sequencing analysis of the BRCA1/2 gene showed 28 types of deleterious mutations in 36 subjects (26.7%), including 13 types of BRCA1 mutations in 17 subjects (12.6%) and 15 types of BRCA2 mutations in 19 subjects (14.1%). Subjects were classified into five groups and 22 subgroups according to their personal and family history of breast and/or ovarian cancer, and the prevalence of deleterious mutations was compared with previously reported data in non-Ashkenazi individuals. Statistical analysis using the Mantel-Haenszel test for groups I through IV revealed that the prevalence of Japanese subjects was significantly higher than that of non-Ashkenazi individuals (P = 0.005, odds ratio 1.87, 95% confidence interval 1.22-2.88). Family history of the probands suffering from breast cancer indicated risk factors for the presence of deleterious mutations of BRCA1/2 as follows: (1) families with breast cancer before age 40 within second degree relatives (P = 0.0265, odds ratio 2.833, 95% confidence interval 1.165-7.136) and (2) families with bilateral breast cancer and/or ovarian cancer within second degree relatives (P = 0.0151, odds ratio 2.88, 95% confidence interval 1.25-6.64).

Entities:  

Mesh:

Year:  2008        PMID: 19016756     DOI: 10.1111/j.1349-7006.2008.00944.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  28 in total

Review 1.  Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.

Authors:  Ava Kwong; Vivian Y Shin; John C W Ho; Eunyoung Kang; Seigo Nakamura; Soo-Hwang Teo; Ann S G Lee; Jen-Hwei Sng; Ophira M Ginsburg; Allison W Kurian; Jeffrey N Weitzel; Man-Ting Siu; Fian B F Law; Tsun-Leung Chan; Steven A Narod; James M Ford; Edmond S K Ma; Sung-Won Kim
Journal:  J Med Genet       Date:  2015-07-17       Impact factor: 6.318

2.  Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).

Authors:  Hideki Tokunaga; Keita Iida; Atsushi Hozawa; Soichi Ogishima; Yoh Watanabe; Shogo Shigeta; Muneaki Shimada; Yumi Yamaguchi-Kabata; Shu Tadaka; Fumiki Katsuoka; Shin Ito; Kazuki Kumada; Yohei Hamanaka; Nobuo Fuse; Kengo Kinoshita; Masayuki Yamamoto; Nobuo Yaegashi; Jun Yasuda
Journal:  PLoS One       Date:  2021-01-11       Impact factor: 3.240

3.  PALB2 mutation in a woman with bilateral breast cancer: A case report.

Authors:  Hiroshi Nakagomi; Yosuke Hirotsu; Kenichiro Okimoto; Ikuko Sakamoto; Kenji Amemiya; Satoko Nakagomi; Takeo Kubota; Hitoshi Mochizuki; Masao Omata
Journal:  Mol Clin Oncol       Date:  2017-03-09

4.  Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.

Authors:  Hiroshi Nakagomi; Ikuko Sakamoto; Yosuke Hirotsu; Kenji Amemiya; Hitoshi Mochiduki; Masao Omata
Journal:  Int J Clin Oncol       Date:  2015-09-28       Impact factor: 3.402

5.  The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.

Authors:  Maiko Okano; Tadashi Nomizu; Kazunoshin Tachibana; Miki Nagatsuka; Masami Matsuzaki; Naoto Katagata; Toru Ohtake; Shiro Yokoyama; Masami Arai; Seigo Nakamura
Journal:  J Hum Genet       Date:  2020-10-12       Impact factor: 3.172

6.  Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.

Authors:  Yosuke Hirotsu; Hiroshi Nakagomi; Ikuko Sakamoto; Kenji Amemiya; Hitoshi Mochizuki; Masao Omata
Journal:  Mol Genet Genomic Med       Date:  2014-12-04       Impact factor: 2.183

Review 7.  Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer.

Authors:  Haeyoung Kim; Doo Ho Choi
Journal:  J Breast Cancer       Date:  2013-12-31       Impact factor: 3.588

8.  miR-1245a promotes the proliferation and invasion of colon adenocarcinoma by targeting BRCA2.

Authors:  Zihao Pan; Wenchang Gan; Caiqian Liang; Yuanxun Xiao; Yu Zhang; Weisheng Yang; Zehui Hou; Shuang Chen; Bing Zeng; Yingru Li
Journal:  Ann Transl Med       Date:  2019-12

9.  Clinical practice guideline for dedicated breast PET.

Authors:  Makoto Hosono; Tsuneo Saga; Kengo Ito; Shinichiro Kumita; Masayuki Sasaki; Michio Senda; Jun Hatazawa; Hiroshi Watanabe; Hiroshi Ito; Shinichi Kanaya; Yuichi Kimura; Hideo Saji; Seishi Jinnouchi; Hiroyoshi Fukukita; Koji Murakami; Seigo Kinuya; Junichi Yamazaki; Mayuki Uchiyama; Koichi Uno; Katsuhiko Kato; Tsuyoshi Kawano; Kazuo Kubota; Takashi Togawa; Norinari Honda; Hirotaka Maruno; Mana Yoshimura; Masami Kawamoto; Yukihiko Ozawa
Journal:  Ann Nucl Med       Date:  2014-05-31       Impact factor: 2.668

10.  Development of Japanese Versions of the Control Preferences Scale and Information Needs Questionnaire: Role of Decision-Making and Information Needs for Japanese Breast Cancer Patients.

Authors:  Kanako Azuma; Takashi Kawaguchi; Takuhiro Yamaguchi; Sayuri Motegi; Kimito Yamada; Kenji Onda; Satoru Iwase; Sakae Unezaki; Hironori Takeuchi
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.